NCT02264678 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT02264678
Title	Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents
Recruitment	Active, not recruiting
Gender	both
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	AstraZeneca
Indications	triple-negative breast cancer HER2 negative breast cancer gastroesophageal junction adenocarcinoma head and neck squamous cell carcinoma gastric adenocarcinoma lung adenocarcinoma lung non-small cell carcinoma ovarian cancer ovary epithelial cancer peritoneum cancer fallopian tube cancer Advanced Solid Tumor
Therapies	Ceralasertib Carboplatin + Ceralasertib Ceralasertib + Durvalumab Ceralasertib + Olaparib
Age Groups:	senior \| adult
Covered Countries	USA \| GBR \| FRA

Additional content available in CKB BOOST